Multimodal strategy to counteract vasodilation in septic shock

Anaesth Crit Care Pain Med. 2023 Jun;42(3):101193. doi: 10.1016/j.accpm.2023.101193. Epub 2023 Jan 5.

Abstract

Early initiation of a multimodal treatment strategy in the management of vasopressors during septic shock has been advocated to reduce delays in restoring adequate organ perfusion and to mitigate side effects associated with the administration of high-dose catecholamines. We provide a review that summarises the pathophysiology of vasodilation, the physiologic response to the vascular response, and the different drugs used in this situation, focusing on the need to combine early different vasopressors. Fluid loading being insufficient for counteracting vasoplegia, norepinephrine is usually the first-line vasopressor used to restore hemodynamics. Norepinephrine sparing is discussed in further detail through the concomitant use of adrenergic, vasopressinergic, and renin-angiotensin systems and the optimisation of endothelial reactivity with methylene blue. A blueprint for the construction of new studies is outlined to address the question of vasopressor selection and timing in septic shock.

Keywords: Catecholamines; Critical care; Septic shock; Vasoactive drugs; Vasoplegia; Vasopressors.

Publication types

  • Review

MeSH terms

  • Catecholamines / therapeutic use
  • Humans
  • Hypotension* / chemically induced
  • Norepinephrine / therapeutic use
  • Shock*
  • Shock, Septic* / drug therapy
  • Vasoconstrictor Agents / therapeutic use
  • Vasodilation

Substances

  • Norepinephrine
  • Vasoconstrictor Agents
  • Catecholamines